{"transactions":[{"id":4165836,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":102465,"kind":"organization","name":"AJU IB Investment Co., Ltd.","position":1,"cik":"0001710065","reported_name":"AJU IB Investment Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2017-11-13T21:29:47.000Z","date":"2017-11-13","kind":"exercise","acquired":false,"shares":888969,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C and Series D Preferred Stock converted into Common Stock on a 2.133-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C and Series D Preferred Stock converted into Common Stock on a 2.133-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C and Series D Preferred Stock converted into Common Stock on a 2.133-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by AJU Life Science Overseas Expansion Platform Fund (\"AJU Platform Fund\"), which is managed by AJU IB Investment Co., Ltd. Ji-won Kim, Kwang-sun Yang and Yong-jin Choi, the directors of AJU Platform Fund, share voting and dispositive control over the shares held by such fund."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":416769},"source":{"system":"sec-edgar","filing":"0000899243-17-026036","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1710065/000089924317026036/doc4.xml","form_type":"4"}},{"id":4165835,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":102465,"kind":"organization","name":"AJU IB Investment Co., Ltd.","position":1,"cik":"0001710065","reported_name":"AJU IB Investment Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2017-11-13T21:29:47.000Z","date":"2017-11-13","kind":"exercise","acquired":false,"shares":4000000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C and Series D Preferred Stock converted into Common Stock on a 2.133-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C and Series D Preferred Stock converted into Common Stock on a 2.133-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C and Series D Preferred Stock converted into Common Stock on a 2.133-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by AJU Life Science Overseas Expansion Platform Fund (\"AJU Platform Fund\"), which is managed by AJU IB Investment Co., Ltd. Ji-won Kim, Kwang-sun Yang and Yong-jin Choi, the directors of AJU Platform Fund, share voting and dispositive control over the shares held by such fund."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1875293},"source":{"system":"sec-edgar","filing":"0000899243-17-026036","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1710065/000089924317026036/doc4.xml","form_type":"4"}},{"id":4165834,"issuer":{"id":47322,"kind":"organization","name":"Apellis Pharmaceuticals, Inc.","symbol":"APLS"},"owners":[{"id":102465,"kind":"organization","name":"AJU IB Investment Co., Ltd.","position":1,"cik":"0001710065","reported_name":"AJU IB Investment Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-13T21:29:47.000Z","date":"2017-11-13","kind":"exercise","acquired":true,"shares":2292062,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C and Series D Preferred Stock converted into Common Stock on a 2.133-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by AJU Life Science Overseas Expansion Platform Fund (\"AJU Platform Fund\"), which is managed by AJU IB Investment Co., Ltd. Ji-won Kim, Kwang-sun Yang and Yong-jin Choi, the directors of AJU Platform Fund, share voting and dispositive control over the shares held by such fund."}],"balance_after":2292062,"source":{"system":"sec-edgar","filing":"0000899243-17-026036","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710065/000089924317026036/doc4.xml","form_type":"4"}},{"id":4260980,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":102465,"kind":"organization","name":"AJU IB Investment Co., Ltd.","position":1,"cik":"0001710065","reported_name":"AJU IB Investment Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series F Preferred Stock","published_at":"2017-07-07T23:13:33.000Z","date":"2017-07-05","kind":"exercise","acquired":false,"shares":483501,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares reported herein are held of record by AJU Growth & Healthcare Fund, which is managed by the Reporting Person."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":48656},"source":{"system":"sec-edgar","filing":"0000899243-17-018090","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1710065/000089924317018090/doc4.xml","form_type":"4"}},{"id":4260979,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":102465,"kind":"organization","name":"AJU IB Investment Co., Ltd.","position":1,"cik":"0001710065","reported_name":"AJU IB Investment Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series E-3 Preferred Stock","published_at":"2017-07-07T23:13:33.000Z","date":"2017-07-05","kind":"exercise","acquired":false,"shares":4411765,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by AJU Life Science Overseas Expansion Platform Fund, which is managed by AJU IB Investment (the \"Reporting Person\")."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":443973},"source":{"system":"sec-edgar","filing":"0000899243-17-018090","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1710065/000089924317018090/doc4.xml","form_type":"4"}},{"id":4260978,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":102465,"kind":"organization","name":"AJU IB Investment Co., Ltd.","position":1,"cik":"0001710065","reported_name":"AJU IB Investment Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-07-07T23:13:33.000Z","date":"2017-07-05","kind":"purchase","acquired":true,"shares":24929,"price":15,"value":373935.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by AJU Life Science Overseas Expansion Platform Fund, which is managed by AJU IB Investment (the \"Reporting Person\")."}],"balance_after":517558,"source":{"system":"sec-edgar","filing":"0000899243-17-018090","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1710065/000089924317018090/doc4.xml","form_type":"4"}},{"id":4260977,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":102465,"kind":"organization","name":"AJU IB Investment Co., Ltd.","position":1,"cik":"0001710065","reported_name":"AJU IB Investment Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-07-07T23:13:33.000Z","date":"2017-07-05","kind":"exercise","acquired":true,"shares":48656,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares reported herein are held of record by AJU Growth & Healthcare Fund, which is managed by the Reporting Person."}],"balance_after":492629,"source":{"system":"sec-edgar","filing":"0000899243-17-018090","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1710065/000089924317018090/doc4.xml","form_type":"4"}},{"id":4260976,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":102465,"kind":"organization","name":"AJU IB Investment Co., Ltd.","position":1,"cik":"0001710065","reported_name":"AJU IB Investment Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-07-07T23:13:33.000Z","date":"2017-07-05","kind":"exercise","acquired":true,"shares":443973,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by AJU Life Science Overseas Expansion Platform Fund, which is managed by AJU IB Investment (the \"Reporting Person\")."}],"balance_after":443973,"source":{"system":"sec-edgar","filing":"0000899243-17-018090","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710065/000089924317018090/doc4.xml","form_type":"4"}}]}